# A Study of AT132 in Young Children With X-Linked Myotubular Myopathy (XLMTM)

> **NCT03199469** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Astellas Gene Therapies** · enrollment: 27 (actual)

## Conditions studied

- X-Linked Myotubular Myopathy

## Interventions

- **GENETIC:** Resamirigene bilparvovec

## Key facts

- **NCT ID:** NCT03199469
- **Lead sponsor:** Astellas Gene Therapies
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-08-02
- **Primary completion:** 2021-09-09
- **Final completion:** 2030-03-31
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03199469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03199469, "A Study of AT132 in Young Children With X-Linked Myotubular Myopathy (XLMTM)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03199469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*